Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Regen Biopharma ( (RGBP) ) just unveiled an announcement.
On August 5, 2025, Regen Biopharma, Inc. entered into a securities purchase agreement with Labrys Fund II LP, resulting in the issuance of a 6% convertible promissory note valued at $100,000. This agreement allows Labrys the option to convert the note into common stock, potentially impacting the company’s stock trading dynamics and financial strategy.
More about Regen Biopharma
Regen Biopharma, Inc. operates in the biotechnology industry, focusing on developing innovative treatments and therapies. The company is involved in the research and development of products aimed at addressing critical medical needs.
Average Trading Volume: 74,769
Technical Sentiment Signal: Sell
Current Market Cap: $1.63M
For a thorough assessment of RGBP stock, go to TipRanks’ Stock Analysis page.